Zacks Investment Research upgraded shares of Urovant Sciences (NASDAQ:UROV) from a hold rating to a buy rating in a research note issued to investors on Thursday morning, Zacks.com reports. Zacks Investment Research currently has $9.75 price objective on the stock.
According to Zacks, “Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company’s product candidate pipeline consists of vibegron, an oral, once-daily, small molecule beta-3 agonist being evaluated in an international pivotal Phase 3 clinical trial for the treatment of overactive bladder. hMaxi-K, is a novel gene therapy being developed for patients with overactive bladder who have failed oral pharmacological therapy. Urovant Sciences Ltd. is based in Floor London, United Kingdom. “
Several other analysts have also commented on the company. HC Wainwright initiated coverage on Urovant Sciences in a report on Monday, March 11th. They issued a buy rating and a $28.00 price objective for the company. SunTrust Banks initiated coverage on Urovant Sciences in a report on Friday, March 15th. They issued a buy rating and a $24.00 price objective for the company. Six research analysts have rated the stock with a buy rating, The company presently has an average rating of Buy and a consensus target price of $21.13.
Urovant Sciences stock opened at $8.05 on Thursday. Urovant Sciences has a 12 month low of $4.05 and a 12 month high of $14.49.
Urovant Sciences (NASDAQ:UROV) last issued its quarterly earnings data on Wednesday, February 13th. The company reported ($0.87) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.09) by $0.22. Analysts predict that Urovant Sciences will post -3.96 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently modified their holdings of UROV. Barclays PLC bought a new stake in shares of Urovant Sciences in the fourth quarter worth $37,000. Two Sigma Investments LP purchased a new position in Urovant Sciences during the fourth quarter valued at $72,000. Weiss Multi Strategy Advisers LLC lifted its position in Urovant Sciences by 38.2% during the fourth quarter. Weiss Multi Strategy Advisers LLC now owns 15,000 shares of the company’s stock valued at $99,000 after purchasing an additional 4,146 shares in the last quarter. Man Group plc purchased a new position in Urovant Sciences during the third quarter valued at $300,000. Finally, Sphera Funds Management LTD. lifted its position in Urovant Sciences by 30.5% during the fourth quarter. Sphera Funds Management LTD. now owns 214,030 shares of the company’s stock valued at $1,410,000 after purchasing an additional 50,000 shares in the last quarter. 22.77% of the stock is owned by institutional investors.
About Urovant Sciences
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Recommended Story: Relative Strength Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.